What to Expect: Merck, Gilead Sciences, and Bristol-Myers Squibb Earnings on Deck
Notable companies expected to release their financial results on Thursday, April 24, include:
Merck & Co., Inc. (NYSE: MRK), known for its innovative portfolio of prescription medicines and vaccines, will report its first-quarter 2025 earnings before the U.S. markets open. Analysts expect earnings per share (EPS) of $2.14 on revenue of $15.33 billion. $MRK rose 2.01% (+$1.54) to close at $78.00 on Thursday.
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company focused on antiviral treatments and oncology, will announce its first-quarter 2025 financial results after market close. Wall Street anticipates EPS of $1.75 and revenue of $6.79 billion. $GILD dipped 0.33% (-$0.35) to finish at $104.53 on Thursday.
Bristol-Myers Squibb Company (NYSE: BMY), a major name in the pharmaceutical space, is set to release its Q1 2025 earnings before the opening bell. The consensus forecast stands at $1.52 EPS on $10.75 billion in revenue. $BMY edged lower by 0.26% (-$0.13), closing Thursday at $49.23.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
© 2025 CRWE PRESS RELEASE. All Rights Reserved.
